Literature DB >> 8556489

Inhibitory effect of 3'-azido-3'-deoxythymidine on proliferative responsiveness of CD8+ lymphocytes to interleukin-2.

L Mercure1, R Lalonde, D Phaneuf, B Brenner, M A Wainberg.   

Abstract

Although several studies have shown that 3'-azido-3'-deoxythymidine (AZT) is not toxic for CD4+ lymphocytes, its effect on CD8+ cells has never been studied in a systematic way. We purified CD8+ cells from the peripheral blood mononuclear cells of both human immunodeficiency virus (HIV)-seronegative and HIV-infected individuals by means of magnetic beads that had been coated with monoclonal antibodies. We report that AZT, but not two other nucleosides tested, inhibited the interleukin-2-dependent proliferation of CD8+ lymphocytes in a dose-dependent manner. No such effect was observed with regard to CD4(+)-enriched populations. The AZT-mediated antiproliferative effect did not appear to be related to either the CD4+ count or to prior treatment with this drug in the case of HIV-seropositive subjects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8556489      PMCID: PMC368294          DOI: 10.1128/cdli.1.4.482-485.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  17 in total

1.  Protection of 3'-azido-3'-deoxythymidine induced toxicity to murine hematopoietic progenitors (CFU-GM, BFU-E and CFU-MEG) with interleukin-1.

Authors:  V S Gallicchio; M A Doukas; B C Hulette; N K Hughes; C Gass
Journal:  Proc Soc Exp Biol Med       Date:  1989-11

2.  Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population.

Authors:  G Pantaleo; S Koenig; M Baseler; H C Lane; A S Fauci
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

3.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

4.  Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group.

Authors:  R Rooke; M Tremblay; H Soudeyns; L DeStephano; X J Yao; M Fanning; J S Montaner; M O'Shaughnessy; K Gelmon; C Tsoukas
Journal:  AIDS       Date:  1989-07       Impact factor: 4.177

5.  3'-Azido-3'-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells.

Authors:  N Dainiak; M Worthington; M A Riordan; S Kreczko; L Goldman
Journal:  Br J Haematol       Date:  1988-07       Impact factor: 6.998

6.  Azidothymidine-induced depression of murine hemopoietic progenitor cells.

Authors:  G Bogliolo; R Lerza; M Mencoboni; A Saviane; I Pannacciulli
Journal:  Exp Hematol       Date:  1988-12       Impact factor: 3.084

7.  Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro.

Authors:  J P Sommadossi; R Carlisle
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

8.  Cellular pharmacology of 3'-azido-3'-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells.

Authors:  J P Sommadossi; R Carlisle; Z Zhou
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

9.  Azidothymidine inhibits mitogen stimulated growth and DNA-repair in human peripheral lymphocytes.

Authors:  B Munch-Petersen
Journal:  Biochem Biophys Res Commun       Date:  1988-12-30       Impact factor: 3.575

10.  Effect of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine on establishment of human immunodeficiency virus type 1 infection in cultured CD8+ lymphocytes.

Authors:  L Mercure; B J Brenner; D Phaneuf; C Tsoukas; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.